Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF

Figure 1.. Number of extra cardiovascular (CV) deaths and heart failure (HF) hospitalizations in a recurrent-events analysis compared with time-to-first event analysis by treatment group.

Figure 2.. Number of patients with ≥1 hospitalization in the dapagliflozin and placebo groups. HF indicates heart failure.

Figure 3.. Variables associated with cardiovascular death or recurrent HF hospitalizations in a multivariable model using the Lin-Wei-Yang-Ying method to model recurrent events. eGFR indicates estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and SBP, systolic blood pressure.

Figure 4.. Cumulative incidence of total heart failure hospitalizations and cardiovascular death. py indicates person-years.

Figure 5.. Effect of dapagliflozin on cardiovascular death or HF hospitalization using a time-to-first event Cox model, recurrent HF hospitalizations or cardiovascular death using the LWYY method and joint frailty model. CV indicates cardiovascular; HF, heart failure; and LWYY, Lin-Wei-Yang-Ying.

Figure 6.. Effect of dapagliflozin compared with placebo on recurrent heart failure hospitalizations or cardiovascular death by subgroups as modeled by the Lin-Wei-Yang-Ying method. AF indicates atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NTproBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.